STOCK TITAN

CVI and Heights disclose 9.9% Phio (PHIO) stake based on warrant holdings

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

CVI Investments, Inc. and Heights Capital Management, Inc. have reported beneficial ownership tied to Phio Pharmaceuticals Corp. common stock. They report 1,194,719 shares beneficially owned, representing 9.9% of Phio’s common stock. This amount consists entirely of shares issuable upon exercise of warrants, rather than currently outstanding shares.

The warrants are subject to a 9.99% beneficial ownership limitation, meaning they cannot be exercised if doing so would push the reporting persons and their affiliates above that threshold. Heights Capital Management, Inc., as investment manager to CVI Investments, Inc., may be deemed to share voting and dispositive power, but both parties disclaim beneficial ownership beyond their pecuniary interest. Phio’s quarterly report indicated 10,764,428 shares outstanding as of November 11, 2025.

Positive

  • None.

Negative

  • None.





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G




Comment for Type of Reporting Person: With respect to Row 6 and Row 8 above, Heights Capital Management, Inc. is the investment manager to CVI Investments, Inc. and as such may exercise voting and dispositive power over the shares reported as beneficially owned by CVI Investments, Inc. herein.


SCHEDULE 13G




Comment for Type of Reporting Person: With respect to Row 6 and Row 8 above, Heights Capital Management, Inc. is the investment manager to CVI Investments, Inc. and as such may exercise voting and dispositive power over the shares reported as beneficially owned by CVI Investments, Inc. herein.


SCHEDULE 13G



CVI Investments, Inc.
Signature:/s/ Sarah Travis
Name/Title:Sarah Travis, Assistant General Counsel and Assistant Secretary of Heights Capital Management, Inc.
Date:02/10/2026
Heights Capital Management, Inc.
Signature:/s/ Sarah Travis
Name/Title:Sarah Travis, Assistant General Counsel and Assistant Secretary
Date:02/10/2026

Comments accompanying signature: Heights Capital Management, Inc. serves as authorized agent of CVI Investments, Inc. pursuant to a Limited Power of Attorney, a copy of which was previously filed.
Exhibit Information

EXHIBIT INDEX EXHIBIT DESCRIPTION 24 Limited Power of Attorney* 99 Joint Filing Agreement* * Previously filed

FAQ

What stake in Phio Pharmaceuticals Corp. (PHIO) is reported in this Schedule 13G/A?

The filing reports beneficial ownership of 1,194,719 Phio common shares, equal to 9.9% of the class. This stake is based on shares issuable upon warrant exercise, using 10,764,428 shares outstanding as of November 11, 2025, from Phio’s quarterly report.

Who are the reporting persons in the Phio Pharmaceuticals (PHIO) Schedule 13G/A?

The reporting persons are CVI Investments, Inc. and Heights Capital Management, Inc.. Heights Capital Management acts as investment manager to CVI Investments and may exercise shared voting and dispositive power over the Phio shares reported as beneficially owned in the statement.

How is the 9.9% ownership in Phio (PHIO) structured according to the filing?

The 9.9% interest reflects shares issuable upon exercise of warrants, not currently outstanding shares. The warrants include a 9.99% beneficial ownership cap, preventing exercise if CVI Investments, Heights Capital, and affiliates would exceed that ownership threshold under Section 13(d).

What limitation applies to the Phio (PHIO) warrants held by the reporting persons?

The warrants cannot be exercised if doing so would cause total beneficial ownership to exceed 9.99%. This limitation applies to the reporting persons, their affiliates, and others whose holdings are aggregated with them for Section 13(d) beneficial ownership calculations under the Exchange Act.

What does the filing say about the reporting persons’ intent regarding control of Phio (PHIO)?

The certification states the securities were not acquired and are not held to change or influence control of Phio Pharmaceuticals. It also notes they are not held in connection with any transaction having that purpose, other than activities solely related to a nomination under Rule 14a-11.

How many Phio (PHIO) shares were outstanding for the ownership calculation?

The ownership percentage uses 10,764,428 Phio common shares outstanding as of November 11, 2025. This figure comes from Phio’s Quarterly Report on Form 10-Q, which the reporting persons reference when calculating their 9.9% beneficial ownership of the company’s common stock.
Phio Pharmaceuticals Corp

NASDAQ:PHIO

PHIO Rankings

PHIO Latest News

PHIO Latest SEC Filings

PHIO Stock Data

17.76M
2.46M
Biotechnology
Pharmaceutical Preparations
Link
United States
KING OF PRUSSIA